{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:37:38Z","timestamp":1782805058451,"version":"3.54.5"},"reference-count":95,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand up to Cancer","doi-asserted-by":"publisher","award":["SU2C-AACR-DT25-17"],"award-info":[{"award-number":["SU2C-AACR-DT25-17"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R37CA237384\u201301A1"],"award-info":[{"award-number":["1R37CA237384\u201301A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020046","name":"Khalifa Bin Zayed Al Nahyan Foundation","doi-asserted-by":"publisher","award":["P50CA221707"],"award-info":[{"award-number":["P50CA221707"]}],"id":[{"id":"10.13039\/100020046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP200173"],"award-info":[{"award-number":["RP200173"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgpath.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Pathology Clinics"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.path.2022.05.004","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T17:07:35Z","timestamp":1659460055000},"page":"491-502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice"],"prefix":"10.1016","volume":"15","author":[{"given":"Chirayu","family":"Mohindroo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"De Jesus-Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Yurgelun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirban","family":"Maitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Mork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florencia","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.path.2022.05.004_bib1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.path.2022.05.004_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1200\/JCO.18.01489","article-title":"Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion","volume":"37","author":"Stoffel","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.path.2022.05.004_bib3","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1002\/cncr.31628","article-title":"Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma","volume":"124","author":"Brand","year":"2018","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.path.2022.05.004_bib4","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/cncr.31242","article-title":"Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy","volume":"124","author":"Dudley","year":"2018","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.path.2022.05.004_bib5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1053\/j.gastro.2014.11.042","article-title":"Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer","volume":"148","author":"Grant","year":"2015","journal-title":"Gastroenterology"},{"issue":"23","key":"10.1016\/j.path.2022.05.004_bib6","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1001\/jama.2018.6228","article-title":"Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer","volume":"319","author":"Hu","year":"2018","journal-title":"Jama"},{"issue":"10","key":"10.1016\/j.path.2022.05.004_bib7","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/jnci\/djy024","article-title":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms","volume":"110","author":"Lowery","year":"2018","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"10.1016\/j.path.2022.05.004_bib8","series-title":"Abstract A02: assessment of germline cancer predisposition genes in 392 unselected pancreatic cancer patients","author":"McKay","year":"2016"},{"issue":"1","key":"10.1016\/j.path.2022.05.004_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41436-018-0009-5","article-title":"Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer","volume":"21","author":"Yurgelun","year":"2019","journal-title":"Genet Med"},{"issue":"6","key":"10.1016\/j.path.2022.05.004_bib10","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1158\/1078-0432.CCR-19-0224","article-title":"Germline DNA sequencing reveals novel mutations predictive of overall survival in a cohort of patients with pancreatic cancer","volume":"26","author":"Goldstein","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.path.2022.05.004_bib11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/1940-6207.CAPR-18-0014","article-title":"High prevalence of hereditary cancer syndromes and outcomes in adults with early-onset pancreatic cancer","volume":"11","author":"Bannon","year":"2018","journal-title":"Cancer Prev Res"},{"issue":"30","key":"10.1016\/j.path.2022.05.004_bib12","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","article-title":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma","volume":"35","author":"Shindo","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.path.2022.05.004_bib13","article-title":"Pancreatic Adenocarcinoma, Version 2.2021","author":"NCCN Guidelines","year":"2021","journal-title":"webpage"},{"issue":"4","key":"10.1016\/j.path.2022.05.004_bib14","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.path.2022.05.004_bib15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.path.2022.05.004_bib16","unstructured":"FDA. FDA approves olaparib for gBRCAm metastatic pancreatic adenocarcinoma. 2019."},{"key":"10.1016\/j.path.2022.05.004_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejca.2017.11.004","article-title":"Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma","volume":"89","author":"Lowery","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.path.2022.05.004_bib18","first-page":"1","article-title":"Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation","volume":"2","author":"Shroff","year":"2018","journal-title":"JCO precision Oncol"},{"key":"10.1016\/j.path.2022.05.004_bib19","unstructured":"FDA. FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. 2017."},{"issue":"23","key":"10.1016\/j.path.2022.05.004_bib20","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-18-0900","article-title":"Immunotherapy in Pancreatic Adenocarcinoma: Beyond \u201cCopy\/Paste\u201d","volume":"27","author":"Hester","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.path.2022.05.004_bib21","first-page":"828","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J\u00a0Immunother"},{"issue":"10","key":"10.1016\/j.path.2022.05.004_bib22","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","volume":"5","author":"O\u2019Reilly","year":"2019","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.path.2022.05.004_bib23","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/annonc\/mdu205","article-title":"A\u00a0phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer","volume":"25","author":"Aglietta","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.path.2022.05.004_bib24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10637-017-0525-1","article-title":"Phase Ib\/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma","volume":"36","author":"Weiss","year":"2018","journal-title":"Invest New Drugs"},{"issue":"11","key":"10.1016\/j.path.2022.05.004_bib25","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","article-title":"Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial","volume":"2","author":"Parikh","year":"2021","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.path.2022.05.004_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Daly","year":"2021","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"11","key":"10.1016\/j.path.2022.05.004_bib27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1940-6207.CAPR-20-0642","article-title":"Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study","volume":"14","author":"Furniss","year":"2021","journal-title":"Cancer Prev Res"},{"issue":"24","key":"10.1016\/j.path.2022.05.004_bib28","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1002\/cncr.29664","article-title":"Identification of germline genetic mutations in patients with pancreatic cancer","volume":"121","author":"Salo-Mullen","year":"2015","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.path.2022.05.004_bib29","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1200\/JCO.2015.64.0730","article-title":"Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers","volume":"34","author":"Vasen","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.path.2022.05.004_bib30","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/bjs5.50180","article-title":"Surveillance for pancreatic cancer in high-risk individuals","volume":"3","author":"Konings","year":"2019","journal-title":"BJS open"},{"issue":"3","key":"10.1016\/j.path.2022.05.004_bib31","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1053\/j.gastro.2018.05.035","article-title":"Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance","volume":"155","author":"Canto","year":"2018","journal-title":"Gastroenterology"},{"issue":"23","key":"10.1016\/j.path.2022.05.004_bib32","first-page":"5360","article-title":"Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas","volume":"56","author":"Goggins","year":"1996","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.path.2022.05.004_bib33","first-page":"60","article-title":"BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian","volume":"7","author":"Friedenson","year":"2005","journal-title":"Medscape Gen Med"},{"issue":"2","key":"10.1016\/j.path.2022.05.004_bib34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cancergencyto.2004.01.032","article-title":"BRCA1 and pancreatic cancer: pedigree findings and their causal relationships","volume":"158","author":"Lynch","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"10.1016\/j.path.2022.05.004_bib35","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1055-9965.EPI-06-0783","article-title":"The prevalence of BRCA2 mutations in familial pancreatic cancer","volume":"16","author":"Couch","year":"2007","journal-title":"Cancer Epidemiol Prev Biomarkers"},{"issue":"3","key":"10.1016\/j.path.2022.05.004_bib36","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jnci\/95.3.214","article-title":"BRCA2 germline mutations in familial pancreatic carcinoma","volume":"95","author":"Hahn","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"13","key":"10.1016\/j.path.2022.05.004_bib37","first-page":"3789","article-title":"Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17","volume":"62","author":"Murphy","year":"2002","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.path.2022.05.004_bib38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1158\/1055-9965.EPI-15-0455","article-title":"Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients","volume":"25","author":"Hu","year":"2016","journal-title":"Cancer Epidemiol Prev Biomarkers"},{"issue":"5924","key":"10.1016\/j.path.2022.05.004_bib39","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.1171202","article-title":"Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene","volume":"324","author":"Jones","year":"2009","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.path.2022.05.004_bib40","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10689-011-9426-1","article-title":"PALB2 mutations in familial breast and pancreatic cancer","volume":"10","author":"Hofstatter","year":"2011","journal-title":"Fam Cancer"},{"issue":"5","key":"10.1016\/j.path.2022.05.004_bib41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.cancergen.2016.03.003","article-title":"Mutation analysis of the PALB2 gene in unselected pancreatic cancer patients in the Czech Republic","volume":"209","author":"Borecka","year":"2016","journal-title":"Cancer Genet"},{"issue":"1","key":"10.1016\/j.path.2022.05.004_bib42","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/genes11010108","article-title":"ATM serine\/threonine kinase and its role in pancreatic risk","volume":"11","author":"Nanda","year":"2020","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.path.2022.05.004_bib43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1158\/2159-8290.CD-11-0194","article-title":"ATM mutations in hereditary pancreatic cancer patients","volume":"2","author":"Roberts","year":"2012","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.path.2022.05.004_bib44","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1053\/j.gastro.2019.01.254","article-title":"Prevalence of germline mutations associated with cancer risk in patients with intraductal papillary mucinous neoplasms","volume":"156","author":"Skaro","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.path.2022.05.004_bib45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrclinonc.2009.237","article-title":"Microsatellite instability in colorectal cancer\u2014the stable evidence","volume":"7","author":"Vilar","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"10.1016\/j.path.2022.05.004_bib46","first-page":"3667","article-title":"Pancreatic cancer in lynch syndrome patients","volume":"8","author":"Bujanda","year":"2017","journal-title":"J\u00a0Cancer"},{"issue":"16","key":"10.1016\/j.path.2022.05.004_bib47","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1001\/jama.2009.1529","article-title":"Risk of pancreatic cancer in families with Lynch syndrome","volume":"302","author":"Kastrinos","year":"2009","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.path.2022.05.004_bib48","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","article-title":"Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.path.2022.05.004_bib49","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.3390\/ijms19113505","article-title":"Emerging role of immune checkpoint blockade in pancreatic cancer","volume":"19","author":"Macherla","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.path.2022.05.004_bib50","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/ejhg.2010.198","article-title":"Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling","volume":"19","author":"McWilliams","year":"2011","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"10.1016\/j.path.2022.05.004_bib51","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1177\/2050640619841989","article-title":"Incidental findings in pancreas screening programs for high-risk individuals: Results from three European expert centers","volume":"7","author":"Ibrahim","year":"2019","journal-title":"United Eur Gastroenterol J"},{"issue":"7","key":"10.1016\/j.path.2022.05.004_bib52","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/01.MP.0000075645.97329.86","article-title":"Loss of Stk11\/Lkb1 expression in pancreatic and biliary neoplasms","volume":"16","author":"Sahin","year":"2003","journal-title":"Mod Pathol"},{"issue":"55","key":"10.1016\/j.path.2022.05.004_bib53","doi-asserted-by":"crossref","first-page":"6908","DOI":"10.1038\/onc.2008.342","article-title":"LKB1; linking cell structure and tumor suppression","volume":"27","author":"Hezel","year":"2008","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.path.2022.05.004_bib54","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.onc.1202486","article-title":"Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1\/STK11, in malignant melanoma","volume":"18","author":"Guldberg","year":"1999","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.path.2022.05.004_bib55","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/gut.2009.198499","article-title":"Peutz\u2013Jeghers syndrome: a systematic review and recommendations for management","volume":"59","author":"Beggs","year":"2010","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.path.2022.05.004_bib56","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.dld.2012.12.018","article-title":"Cancer risk associated with STK11\/LKB1 germline mutations in Peutz\u2013Jeghers syndrome patients: Results of an Italian multicenter study","volume":"45","author":"Resta","year":"2013","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.path.2022.05.004_bib57","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/MPA.0000000000001293","article-title":"Pancreatic cancer early detection and interception in an atypical case of Peutz-Jeghers syndrome","volume":"48","author":"Mork","year":"2019","journal-title":"Pancreas"},{"issue":"9","key":"10.1016\/j.path.2022.05.004_bib58","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/MPA.0000000000001145","article-title":"Pancreatitis-associated genes and pancreatic cancer risk: a systematic review and meta-analysis","volume":"47","author":"Cazacu","year":"2018","journal-title":"Pancreas"},{"issue":"9","key":"10.1016\/j.path.2022.05.004_bib59","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41395-018-0194-5","article-title":"Hereditary pancreatitis in the United States: survival and rates of pancreatic cancer","volume":"113","author":"Shelton","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.path.2022.05.004_bib60","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1542-3565(04)00013-8","article-title":"Clinical and genetic characteristics of hereditary pancreatitis in Europe","volume":"2","author":"Howes","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.path.2022.05.004_bib61","doi-asserted-by":"crossref","first-page":"652","DOI":"10.4161\/cbt.2.6.530","article-title":"Polymorphisms of SPINK1 N34S and CFTR in patients with sporadic and familial pancreatic cancer","volume":"2","author":"Matsubayashi","year":"2003","journal-title":"Cancer Biol Ther"},{"issue":"31","key":"10.1016\/j.path.2022.05.004_bib62","doi-asserted-by":"crossref","first-page":"50824","DOI":"10.18632\/oncotarget.15137","article-title":"Lack of association between the pancreatitis risk allele CEL-HYB and pancreatic cancer","volume":"8","author":"Shindo","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.path.2022.05.004_bib63","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000513966","article-title":"Multi-Gene Panel Testing in Gastroenterology: Are We Ready for the Results?","volume":"28","author":"Pereira","year":"2021","journal-title":"GE-Portuguese J Gastroenterol"},{"issue":"6","key":"10.1016\/j.path.2022.05.004_bib64","doi-asserted-by":"crossref","first-page":"a002154","DOI":"10.1101\/mcs.a002154","article-title":"The impact of hereditary cancer gene panels on clinical care and lessons learned","volume":"3","author":"Okur","year":"2017","journal-title":"Mol Case Stud"},{"issue":"7","key":"10.1016\/j.path.2022.05.004_bib65","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/gim.2013.73","article-title":"ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing","volume":"15","author":"Green","year":"2013","journal-title":"Genet Med"},{"issue":"9","key":"10.1016\/j.path.2022.05.004_bib66","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2017.11137","article-title":"Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing","volume":"318","author":"Mandelker","year":"2017","journal-title":"Jama"},{"key":"10.1016\/j.path.2022.05.004_bib67","unstructured":"NCCN. NCCN Guidelines Version 2.2021 Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. 2021."},{"key":"10.1016\/j.path.2022.05.004_bib68","series-title":"Multi-Gene panel testing in breast cancer management","first-page":"121","author":"Fountzilas","year":"2018"},{"issue":"3","key":"10.1016\/j.path.2022.05.004_bib69","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jamaoncol.2015.28","article-title":"Multigene panel testing in oncology practice: how should we respond?","volume":"1","author":"Kurian","year":"2015","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.path.2022.05.004_bib70","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/bjc.2017.19","article-title":"Overall survival and clinical characteristics of BRCA mutation carriers with stage I\/II pancreatic cancer","volume":"116","author":"Golan","year":"2017","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.path.2022.05.004_bib71","doi-asserted-by":"crossref","first-page":"e000578","DOI":"10.1136\/esmoopen-2019-000578","article-title":"Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies","volume":"5","author":"Pokataev","year":"2020","journal-title":"ESMO open"},{"issue":"3","key":"10.1016\/j.path.2022.05.004_bib72","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/gutjnl-2019-319984","article-title":"DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives","volume":"70","author":"Perkhofer","year":"2021","journal-title":"Gut"},{"issue":"13","key":"10.1016\/j.path.2022.05.004_bib73","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O\u2019Reilly","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.path.2022.05.004_bib74","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.path.2022.05.004_bib75","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1158\/1535-7163.MCT-12-0950","article-title":"RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib","volume":"12","author":"Min","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.path.2022.05.004_bib76","unstructured":"A Randomized Study of Olaparib or Placebo in Patients With Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation, The APOLLO Trial."},{"issue":"11","key":"10.1016\/j.path.2022.05.004_bib77","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1158\/1535-7163.MCT-19-0208","article-title":"ATM dysfunction in pancreatic adenocarcinoma and associated therapeutic implications","volume":"18","author":"Armstrong","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.path.2022.05.004_bib78","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jamaoncol.2021.0006","article-title":"Olaparib monotherapy for previously treated pancreatic cancer with DNA damage repair genetic alterations other than germline BRCA variants: findings from 2 phase 2 nonrandomized clinical trials","volume":"7","author":"Javle","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.path.2022.05.004_bib79","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/15384101.2017.1312236","article-title":"Susceptibility of ATM-deficient pancreatic cancer cells to radiation","volume":"16","author":"Ayars","year":"2017","journal-title":"Cell Cycle"},{"issue":"15","key":"10.1016\/j.path.2022.05.004_bib80","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1158\/0008-5472.CAN-19-0761","article-title":"Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy","volume":"79","author":"Zhang","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.path.2022.05.004_bib81","unstructured":"Testing the Addition of an Anti-cancer Drug, BAY 1895344 ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors."},{"key":"10.1016\/j.path.2022.05.004_bib82","series-title":"A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer","author":"Chu","year":"2020"},{"key":"10.1016\/j.path.2022.05.004_bib83","unstructured":"Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas."},{"issue":"15","key":"10.1016\/j.path.2022.05.004_bib84","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMp1709968","article-title":"First FDA approval agnostic of cancer site-when a biomarker defines the indication","volume":"377","author":"Lemery","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.path.2022.05.004_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: Results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.path.2022.05.004_bib86","unstructured":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158\/KEYNOTE-158)."},{"key":"10.1016\/j.path.2022.05.004_bib87","unstructured":"A Study of XmAb\u00ae22841 Monotherapy & in Combination w\/Pembrolizumab in Subjects w\/Selected Advanced Solid Tumors."},{"key":"10.1016\/j.path.2022.05.004_bib88","unstructured":"Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors."},{"key":"10.1016\/j.path.2022.05.004_bib89","unstructured":"Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced\/Metastatic Adenocarcinoma."},{"key":"10.1016\/j.path.2022.05.004_bib90","series-title":"Ipilimumab and gemcitabine for advanced pancreas cancer: a phase Ib study","author":"Kalyan","year":"2016"},{"key":"10.1016\/j.path.2022.05.004_bib91","series-title":"Results of the phase Ib study of ipilimumab and gemcitabine for advanced pancreas cancer","author":"Mohindra","year":"2015"},{"issue":"5","key":"10.1016\/j.path.2022.05.004_bib92","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jama.2019.9690","article-title":"Screening for pancreatic cancer","volume":"322","author":"Lucas","year":"2019","journal-title":"Jama"},{"key":"10.1016\/j.path.2022.05.004_bib93","author":"Network"},{"issue":"6","key":"10.1016\/j.path.2022.05.004_bib94","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/gutjnl-2020-323611","article-title":"Long-term yield of pancreatic cancer surveillance in high-risk individuals","volume":"71","author":"Overbeek","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.path.2022.05.004_bib95","series-title":"Improving cascade genetic testing for families with inherited pancreatic cancer (PDAC) risk: the GENetic Education, Risk Assessment and TEsting (GENERATE) study","author":"Yurgelun","year":"2020"}],"container-title":["Surgical Pathology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918122000307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918122000307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:43:04Z","timestamp":1761748984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875918122000307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1875918122000307"],"URL":"https:\/\/doi.org\/10.1016\/j.path.2022.05.004","relation":{},"ISSN":["1875-9181"],"issn-type":[{"value":"1875-9181","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"Surgical Pathology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.path.2022.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}